Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb;28(1):26-33.
doi: 10.1097/MOP.0000000000000298.

Future directions in the treatment of osteosarcoma

Michael W Bishop  1 , Katherine A Janeway, Richard Gorlick
Affiliations
Review

Future directions in the treatment of osteosarcoma

Michael W Bishop et al. Curr Opin Pediatr. 2016 Feb.

Abstract

Purpose of review: Overall survival rates for osteosarcoma have remained essentially unchanged over the past 3 decades despite attempts to improve outcome via dose intensification and modification based on response. This review describes recent findings from contemporary clinical trials, advances in the comprehension of osteosarcoma biology and genomic complexity, and potential opportunities using targeted and immune-mediated therapies.

Recent findings: Recent results from international collaborative trials have failed to demonstrate an ability to improve outcomes using a design in which the randomized question is dictated based on histologic response to preoperative chemotherapy. Novel prognostic markers assessable at diagnosis are vital to identifying subsets of osteosarcoma. Clinical trials focus has now shifted to serial phase II studies of novel agents to evaluate for activity in recurrent and refractory disease. In-depth analyses have revealed profound genomic instability and heterogeneity across patients, with nearly universal TP53 aberration. Although driver mutational events have not clearly been established, frequent derangements in specific pathways may suggest opportunities for therapeutic exploitation. Genomic complexity may lend support to a role for immune-mediated therapies.

Summary: Rigorous preclinical investigations are potentially generating novel strategies for the treatment of osteosarcoma that will inform the next generation of clinical trials, with the opportunity to identify agents that will improve survival outcomes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A CIRCOS plot demonstrates genomic complexity within a single osteosarcoma tumor sample. Chromosomes are depicted on the outer most track. A blue-red heatmap circle indicates copy number ratio estimates from whole genome sequencing. Interchromosomal and intrachromosomal rearrangements are represented by lines and arcs within the heat-map circle. C>T (green) and C>G (yellow) mutations are plotted outside the heat-map circle. An area of numerous C>T and C>G mutations in concert with significant intrachromosomal rearrangements at chromosome 15 suggests a focal area of hypermutation or “kataegis”.
Figure 2
Figure 2
A karyotype of a patient with osteosarcoma demonstrates multiple structural and numeric abnormalities.
See this image and copyright information in PMC

References

    1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 2009;115:1531–1543. - PMC - PubMed
    1. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–2011. - PubMed
    1. Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M, LaQuaglia M. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993;11:449–453. - PubMed
    1. Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jurgens H, Gadner H, Bielack SS. Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2003;21:2011–2018. - PubMed
    1. Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Bohling T, Calaminus G, Capra M, Deffenbaugh C, Dhooge C, Eriksson M, Flanagan AM, Gelderblom H, Goorin A, Gorlick R, Gosheger G, Grimer RJ, Hall KS, Helmke K, Hogendoorn PC, Jundt G, Kager L, Kuehne T, Lau C, Letson GD, Meyer J, Meyers P, Morris C, Mottl H, Nadel H, Nagarajan R, Randall RL, Schomberg P, Schwarz R, Teot LA, Sydes MR, Bernstein M. Euramos-1, an international randomised study for osteosarcoma: Results from pre-randomisation treatment. Ann Oncol. 2014 [This article details the international collaborative trial EURAMOS-1, and the regulatory, financial and operational challenges faced by study groups in its implementation.] - PMC - PubMed

Substances